Multiple Ascending Dose Putative Cognitive Enhancer VU319

Summary

This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.

Timeline

Start

2021-05-25

Primary completion

2021-05-25

Completion

2021-05-25

Outcome

Outcome not reported

Stopped: “Further development has been outlicensed to Acadia Pharmaceuticals”

Drugs

Indications